ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • anti-citrullinated protein/peptide antibodies (ACPA) and methotrexate (MTX)
  • Anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid arthritis (RA)
  • anti-citrullinated protein/peptide antibodies (ACPA) and therapeutic targeting
  • anti-cN1A antibodies
  • Anti-depressant
  • Anti-DNA
  • anti-DNA and antibodies
  • anti-DNA and lupus nephritis
  • Anti-drug antibodies
  • anti-drug antibodies and anti-TNF therapy
  • anti-dsDNA
  • anti-dsDNA and anti-Smith
  • anti-dsDNA and cytokines
  • anti-dsDNA and glomerulonephritis
  • anti-dsDNA and immunoglobulin (IG)
  • anti-dsDNA and nephritis
  • anti-dsDNA and neuropsychiatric disorders
  • anti-dsDNA and Reproductive Health
  • Anti-GBM Disease (Goodpasture's)
  • Anti-histone antibodies
  • Anti-La
  • anti-mitochondria antibody
  • anti-mitochondria antibody and calcinosis
  • anti-mitochondria antibody and prognostic factors
  • Anti-MPP1
  • anti-mutated citrullinated vimentin
  • anti-phosphatidylserine/prothrombin antibodies
  • Anti-resorptives
  • anti-ribosomal P
  • anti-RNA antibodies
  • Anti-Ro
  • Anti-Synthetase Syndrome and malignancy
  • Anti-TNF Drugs
  • anti-TNF therapy
  • anti-TNF therapy and arthritis
  • anti-TNF therapy and axial spondyloarthritis
  • anti-TNF therapy and biologic drugs
  • anti-TNF therapy and biomarkers
  • anti-TNF therapy and biosimilars
  • anti-TNF therapy and bone metabolism
  • Anti-TNF therapy and cancer
  • Anti-TNF therapy and certolizumab pegol
  • anti-TNF therapy and clinical practice
  • anti-TNF therapy and Clinical Response
  • anti-TNF therapy and cytokines
  • anti-TNF therapy and Disease Activity
  • anti-TNF therapy and drug safety
  • anti-TNF therapy and dry eyes
  • anti-TNF therapy and epidemiologic methods
  • anti-TNF therapy and extraarticular manifestations
  • anti-TNF therapy and eye disease
  • anti-TNF therapy and Femur Fractures
  • Anti-TNF therapy and fractures
  • anti-TNF therapy and functional status
  • anti-TNF therapy and Golimumab
  • Anti-TNF therapy and health care cost
  • anti-TNF therapy and Immunotherapy
  • Anti-TNF therapy and infection
  • anti-TNF therapy and inflammation
  • anti-TNF therapy and infliximab
  • Anti-TNF therapy and juvenile idiopathic arthritis (JIA)
  • anti-TNF therapy and magnetic resonance imaging (MRI)
  • anti-TNF therapy and methotrexate (MTX)
  • Anti-TNF therapy and monocytes
  • anti-TNF therapy and neurologic involvement
  • Anti-TNF therapy and pediatric rheumatology
  • anti-TNF therapy and positron emission tomography (PET)
  • anti-TNF therapy and prognostic factors
  • anti-TNF therapy and psoriasis
  • Anti-TNF therapy and psoriatic arthritis
  • anti-TNF therapy and quality of life
  • anti-TNF therapy and radiography
  • anti-TNF therapy and randomized trials
  • anti-TNF therapy and registries
  • anti-TNF therapy and registry
  • anti-TNF therapy and remission
  • anti-TNF therapy and rheumatic disease
  • Anti-TNF therapy and rheumatoid arthritis
  • Anti-TNF therapy and rheumatoid arthritis (RA)
  • Anti-TNF therapy and rituximab
  • anti-TNF therapy and safety
  • anti-TNF therapy and spine involvement
  • Anti-TNF therapy and spondylarthritis
  • Anti-TNF therapy and spondylarthropathy
  • anti-TNF therapy and taper
  • anti-TNF therapy and tnf
  • anti-TNF therapy and tocilizumab
  • anti-TNF therapy and tolerance
  • Anti-TNF therapy and treatment
  • Anti-TNF therapy and tuberculosis
  • anti-TNF therapy and tumor necrosis factor (TNF)
  • anti-TNF therapy and uveitis
  • anti-TNF therapy and vaccines
  • Anti-TNF therapy and vasculitis
  • anti-β2-glycoprotein I Domain1 and IgA isotype
  • antiangiogenetic chemokines and IL-33
  • antibiotic therapy
  • Antibiotics
  • antibiotics and dermatomyositis
  • antibiotics and Electronic Health Record
  • Antibodies
  • antibodies and arthritis
  • antibodies and autoantibodies
  • Antibodies and autoimmune diseases
  • antibodies and big data
  • Antibodies and biomarkers
  • antibodies and citrullination
  • antibodies and diagnosis
  • antibodies and Diagnostic Tests
  • antibodies and flow cytometry
  • antibodies and inflammatory arthritis
  • antibodies and interleukins (IL)
  • antibodies and juvenile idiopathic arthritis-enthesitis (ERA)
  • Antibodies and myositis
  • antibodies and pediatric rheumatology
  • antibodies and pediatrics
  • antibodies and pregnancy
  • antibodies and rheumatic disease
  • antibodies and rheumatoid arthritis (RA)
  • antibodies and scleroderma
  • antibodies and scleroderma-like conditions
  • antibodies and spondylarthropathy
  • antibodies and statin-induced myopathies
  • antibodies and synovial cells
  • antibodies and systemic lupus erythematosus (SLE)
  • antibodies and systemic sclerosis
  • Antibodies and tocilizumab
  • antibodies and tofacitinib
  • antibodies and tolerance
  • antibodies and tumor necrosis factor (TNF)
  • antibodies and vaccines
  • antibodies and vasculitis
  • antibody
  • Antibody microarray
  • antibody microarray and biomarkers
  • Anticardiolipin
  • anticardiolipin and systemic lupus erythematosus (SLE)
  • Anticoagulation
  • Anticoagulation and antiphospholipid
  • Anticoagulation and antiphospholipid syndrome
  • Anticoagulation and systemic lupus erythematosus (SLE)
  • anticoagulation and vasculitis
  • antigen and human leukocyte antigens (HLA)
  • Antigen Bead Array and Enzyme-Linked Immunoabsorbant Assays (ELISA)
  • antigen RA
  • antigen RA and rheumatoid arthritis (RA)
  • antigen specific Th17 cells and enzyme-linked immunospot assay (ELISPOT)
  • antigen-presenting cells
  • antigen-presenting cells and axial spondyloarthritis
  • antigen-presenting cells and myositis
  • antigen-presenting cells and rheumatoid arthritis (RA)
  • antigen-presenting cells and tolerance
  • Antigens
  • antigens and autoantigens
  • antigens and biomarkers
  • antigens and genomics
  • antigens and vasculitis
  • antiinflammatory
  • Antimalarial drugs
  • antimalarial drugs and cardiomyopathy
  • antimalarial drugs and drug toxicity
  • Antimalarial drugs and systemic lupus erythematosus (SLE)
  • antimalarial drugs and treatment
  • Antinuclear antibodies (ANA)
  • Antinuclear antibodies (ANA) and autoantibodies
  • antinuclear antibodies (ANA) and biomarkers
  • Antinuclear antibodies (ANA) and health care cost
  • antinuclear antibodies (ANA) and laboratory tests
  • antinuclear antibodies (ANA) and musculoskeletal disorders
  • antinuclear antibodies (ANA) and systemic sclerosis
  • Antinuclear antibodies (ANA) and thrombosis
  • antinuclear antibodies (ANA) and Utility
  • antinucleosome antibodies
  • Antinucleosome antibodies and autoantibodies
  • Antinucleosome antibodies and systemic lupus erythematosus (SLE)
  • antioxidant
  • antioxidant and MRL-lpr mouse
  • Antioxidants
  • antioxidants and mouse model
  • antioxidants and osteoarthritis
  • antioxidants and osteoclastogenesis
  • Antiphospholipid
  • antiphospholipid and antiphospholipid antibodies
  • antiphospholipid and antiphospholipid syndrome
  • antiphospholipid and microbiome
  • antiphospholipid and monocytes
  • Antiphospholipid and thrombosis
  • antiphospholipid and vasculitis
  • Antiphospholipid antibodies
  • antiphospholipid antibodies and antiphospholipid syndrome
  • antiphospholipid antibodies and aPL
  • antiphospholipid antibodies and biomarkers
  • antiphospholipid antibodies and cardiovascular disease
  • antiphospholipid antibodies and Cell Signaling
  • antiphospholipid antibodies and cerebrovascular disease
  • Antiphospholipid Antibodies and giant cell arteritis
  • antiphospholipid antibodies and interferons
  • Antiphospholipid Antibodies and myocardial involvement
  • Antiphospholipid antibodies and pregnancy
  • Antiphospholipid antibodies and systemic lupus erythematosus (SLE)
  • « Previous Page
  • 1
  • 2
  • 3
  • [4]
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology